Barbara Bispham joined Crescent as general counsel and corporate secretary in January 2025. Prior to joining Crescent, she served as senior vice president, general counsel and corporate secretary at Sail Biomedicines, where she oversaw the company’s legal and intellectual property operations. Prior to Sail, Ms. Bispham served as senior vice president, general counsel and corporate secretary at Senda Biosciences, a biotechnology company and subsidiary of Flagship Pioneering, until it merged with LARONDE, also a Flagship Pioneering subsidiary, to form Sail Biomedicines in October 2023. Prior to joining Senda, Ms. Bispham held positions of increasing responsibility at BridgeBio Pharma, most recently serving as vice president, head of legal, where she oversaw legal, transactional, employment, governance, litigation, privacy, compliance and intellectual property operations. While at BridgeBio Pharma, Ms. Bispham supported key activities in connection with the commercialization of the company’s first two FDA-approved drugs, NULIBRY^® and TRUSELTIQ^®. Earlier, she was a member of Goodwin Procter LLP’s Tech and Life Sciences Group and a corporate associate at Cooley LLP. Ms. Bispham earned her JD from Cornell Law School and her BA at the University of Pennsylvania.